Are there any side effects or risks associated with the therapy
Peptide Vials (NAD+, 500 mg each): 8 weeks 11 vials (total 5,075 mg used) 12 weeks 16 vials (total 7,875 mg used) 16 weeks 22 vials (total 10,675 mg used) Insulin Syringes (U100, 1 mL): Per week: 7 syringes (1/day) 8 weeks: 56 syringes 12 weeks: 84 syringes 16 weeks: 112 syringes Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution
It is a dimeric complex composed of: The calcitonin receptor (CTR) , a GPCR The RAMP protein (Receptor Activity Modifying Protein), 1, 2 or 3 Depending on the type of RAMP, three different amylin receptors arise: AMY1 : CTR + RAMP1, primarily in the CNS (area postrema, hypothalamus) AMY2 : CTR + RAMP2, peripheral tissues AMY3 : CTR + RAMP3, bone tissue, some CNS Cagrilintide activates all three amylin receptors , but the primary therapeutic effect is via AMY1 in the area postrema (brainstem, where nausea and satiety signals are processed)